Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Biotech Releases White Paper on Alzheimer's Disease Candidate

Share on Stocktwits


A company focused on treatment of neurodegenerative diseases has issued a white paper discussing its lead candidate.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) has issued a white paper in association with its participation in the 2018 Alzheimer's Association International Conference (AAIC), according to a July 31 press release. The company made a poster presentation at the conference regarding its lead candidate, humanized PMN310, which it says "shows unrivaled selectivity for native toxic AβO derived from human AD brains, with no off-target binding to Aβ monomers or plaque."

At the AAIC, one area of focus was "the causative role of amyloid-beta oligomers (AβO) in the development and progression of Alzheimer's disease (AD) and the importance of neutralizing AβO toxicity represented a common theme across multiple oral presentations and posters," the company stated.

The ProMIS white paper, titled "State of the Art at AAIC 2018," addresses that theme, exploring the idea that "targeting toxic amyloid-beta oligomers offers renewed hope for treatment of Alzheimer's disease."

"We believe the oligomer selectivity of PMN310 supports a potential best in class product profile compared to other therapeutic antibodies currently showing promising results in clinical trials," ProMIS President and CEO Dr. Elliot Goldstein stated.

Humanized PMN310 "is on track to enter Phase 1 clinical testing in the second half of 2019 and will include biomarker assessment as an integral part of the study design," according to the company.


1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe